<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01252355</url>
  </required_header>
  <id_info>
    <org_study_id>EFC6058</org_study_id>
    <secondary_id>2010-023172-12</secondary_id>
    <secondary_id>U1111-1115-2414</secondary_id>
    <nct_id>NCT01252355</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta</brief_title>
  <acronym>TERACLES</acronym>
  <official_title>A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis Who Are Treated With Interferon-beta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective was to demonstrate the effect of teriflunomide, in comparison to
      placebo, on frequency of Multiple Sclerosis (MS) relapses in patients with relapsing forms of
      MS who are treated with Interferon-beta (IFN-beta).

      The secondary objectives were:

        -  Assess the effect of teriflunomide, in comparison to placebo, when added to IFN-beta on:

             -  Disease activity as measured by brain Magnetic Resonance Imaging (MRI)

             -  Disability progression

             -  Burden of disease and disease progression as measured by brain MRI

        -  Evaluate the safety and tolerability of teriflunomide when added to IFN-beta therapy

        -  Assess the pharmacokinetics of teriflunomide in use in addition to baseline IFN-beta
           therapy

        -  Assess associations between variations in genes and clinical outcomes (safety and
           efficacy)

        -  Assess other measures of efficacy of teriflunomide such as fatigue and health-related
           quality of life

        -  Assess measures of health economics (hospitalization due to relapse, including the
           length of stay and any admission to intensive care unit)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study period per patient was expected to be between 56 and 160 weeks depending on when
      the patient was randomized and this included the following:

        -  a screening period up to 4 weeks,

        -  a treatment period expected to be between 48 and 152 weeks,

        -  4-week post rapid elimination follow-up period.

      Patients were to continue on treatment until a fixed common end date which was approximately
      48 weeks after randomization of the last patient.

      For those patients who completed the treatment period, a long term extension study of
      approximately 1 year (including teriflunomide alone) was initially planned to be proposed.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision to prematurely stop the study, not linked to any safety concern.
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized Relapse Rate (ARR) (Poisson Regression Estimates)</measure>
    <time_frame>Up to a maximum of 108 weeks depending on time of enrollment</time_frame>
    <description>ARR is the total number of confirmed relapses that occurred during the treatment period divided by the total number of patient-years treated. Each episode of relapse (appearance, or worsening of a clinical symptom that was stable for at least 30 days, that persisted for a minimum of 24 hours in the absence of fever) was to be confirmed by an increase in Expanded Disability Status Scale (EDSS) score or Functional System scores. To account for the different treatment durations among participants, a Poisson regression model with robust error variance was used (total number of confirmed relapses as response variable; log-transformed treatment duration as &quot;offset&quot; variable; treatment group, region of enrollment and IFN-beta dose stratum, and number of relapses in the year prior to randomization as covariates).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain Magnetic Resonance Imaging (MRI) Assessment: Number of Gadolinium Enhancing (Gd-enhancing) T1-lesions Per Scan (Poisson Regression Estimates)</measure>
    <time_frame>Up to a maximum of 108 weeks depending on time of enrollment</time_frame>
    <description>Number of Gd-enhancing T1-lesions per scan is the total number of Gd-enhancing T1-lesions that occurred during the treatment period divided by the total number of scans performed during the treatment period. To account for the different number of scans among participants, a Poisson regression model with robust error variance was used (total number of Gd-enhancing T1-lesions as response variable; log-transformed number of scans as offset variable; treatment group, region of enrollment, IFN-beta dose stratum and baseline number of Gd-enhancing T1-lesions as covariates).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 12-Week Sustained Disability Progression</measure>
    <time_frame>Up to a maximum of 108 weeks depending on time of enrollment</time_frame>
    <description>The 12-week sustained disability progression was defined as an increase from baseline of at least 1-point in EDSS score (at least 0.5-point for participants with baseline EDSS score &gt;5.5) that persisted for at least 12 weeks. Probability of disability progression was to be estimated using Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain MRI Assessment: Volume of Gd-enhancing T1-lesions Per MRI Scan</measure>
    <time_frame>Up to a maximum of 108 weeks depending on time of enrollment</time_frame>
    <description>Total volume of Gd-enhancing T1-lesions per scan is the sum of the volumes of Gd-enhancing T1-lesions observed during the treatment period divided by the total number of scans performed during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain MRI Assessment: Change From Baseline in Total Lesion Volume (Burden of Disease) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The total lesion volume (burden of disease) is the total volumes of hyperintense on T2 plus hypointense on T1 as measured by MRI scan. Least-square means were estimated using a Mixed-effect model with repeated measures (MMRM) on cubic root transformed volume data with factors for treatment, region, IFN-beta dose stratum, visit, treatment-by-visit interaction, cubic root transformed baseline burden of disease, and baseline-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Relapse: Kaplan-Meier Estimates of the Probability of no Relapse at Week 24, 48, and 72</measure>
    <time_frame>Up to a maximum of 108 weeks depending on time of enrollment</time_frame>
    <description>Probability of no relapse at 24, 48 and 72 weeks was estimated using Kaplan-Meier method on the time to relapse defined as the time from randomization to first EDSS confirmed relapse. Participants free of confirmed relapse (no EDSS confirmed relapse observed on treatment) were censored at the date of the last study drug intake. Kaplan-Meier method consists in computing probabilities of non-occurrence of event at any observed time of event and multiplying successive probabilities for time &lt;=t by any earlier computed probabilities to estimate the probability of being event-free for the amount of time t.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fatigue Impact Scale (FIS) Total Score at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>FIS is a participant-reported scale that qualifies the impact of fatigue on daily life in participants with MS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short Form Generic Health Survey - 36 Items, Version 2 (SF-36v2) Summary Scores at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>SF-36 scale is a generic, self-administered, health-related quality-of-life (QOL) instrument.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource Utilization When Relapse</measure>
    <time_frame>Up to a maximum of 108 weeks depending on time of enrollment</time_frame>
    <description>Resource utilization each time a participant experiences an MS relapse, specifically the number of hospitalizations, the number of over night spent in the hospital and number of intensive care admissions if hospitalized were to be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overview of Adverse Events (AEs)</measure>
    <time_frame>First study drug intake up to 28 days after last study drug intake, for up to 112 weeks</time_frame>
    <description>AEs are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Liver Function: Number of Participants With Potentially Clinically Significant Abnormalities (PCSA)</measure>
    <time_frame>First study drug intake up to 28 days after last study drug intake, for up to 112 weeks</time_frame>
    <description>PCSA values are abnormal values considered medically important by the Sponsor according to predefined criteria based on literature review. Hepatic parameters thresholds were defined as follows: Alanine Aminotransferase (ALT) &gt;3, 5 or 10 Upper Limit of Normal (ULN); Aspartate Aminotransferase (AST) &gt;3, 5 or 10 ULN; Alkaline Phosphatase &gt;1.5 ULN; Total Bilirubin (TB) &gt;1.5 ULN; and ALT &gt;3 ULN and TB &gt;2 ULN.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">534</enrollment>
  <condition>Multiple Sclerosis Relapse</condition>
  <arm_group>
    <arm_group_label>Teriflunomide 7 mg + IFN-beta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teriflunomide 7 milligram (mg) once a day concomitantly with IFN-beta therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teriflunomide 14 mg + IFN-beta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teriflunomide 14 mg once a day concomitantly with IFN-beta therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + IFN-beta</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (for teriflunomide) once a day concomitantly with IFN-beta therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriflunomide</intervention_name>
    <description>Film-coated tablet
Oral administration</description>
    <arm_group_label>Teriflunomide 7 mg + IFN-beta</arm_group_label>
    <arm_group_label>Teriflunomide 14 mg + IFN-beta</arm_group_label>
    <other_name>HMR1726</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for teriflunomide)</intervention_name>
    <description>Film-coated tablet
Oral administration</description>
    <arm_group_label>Placebo + IFN-beta</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon-beta (IFN-beta)</intervention_name>
    <description>Any of the IFN-beta which are approved for marketed use in the country where the patient is enrolled.
Administration according to the package insert.</description>
    <arm_group_label>Teriflunomide 7 mg + IFN-beta</arm_group_label>
    <arm_group_label>Teriflunomide 14 mg + IFN-beta</arm_group_label>
    <arm_group_label>Placebo + IFN-beta</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Patient with relapsing forms of MS treated with IFN-beta

          -  Stable dose of IFN-beta (approved brand) for at least 6 months prior to randomization

          -  Disease activity in the 12 months prior to randomization and after first 3 months of
             IFN-beta treatment (defined by at least 1 relapse supported by EDSS or equivalent
             neurological examination, or, at least 1 brain or spinal cord MRI with at least one T1
             gadolinium enhancing lesion)

        Exclusion criteria:

          -  McDonald criteria for MS diagnosis not met at time of screening visit

          -  EDSS score greater than (&gt;) 5.5 at randomization visit

          -  A relapse within 30 days prior randomization

          -  Persistent significant or severe infection

          -  Patients must not have used adrenocorticotrophic hormone or systemic corticosteroids
             for 2 weeks prior to randomization

          -  Prior or concomitant use of cytokine therapy (except baseline interferons), glatiramer
             acetate or intravenous immunoglobulins in the 3 months preceding randomization

          -  Liver function impairment or persisting elevations (confirmed by retest) of alanine
             aminotransferase (ALT), aspartate aminotransferase (AST), or direct bilirubin greater
             than 2 times the upper limit of normal range (ULN)

          -  Active hepatitis or hepatobiliary disease or known history of severe hepatitis

          -  Pregnant or breast-feeding women or those who were planning to become pregnant during
             the study

          -  Significantly impaired bone marrow function or significant anemia, leukopenia, or
             thrombocytopenia

          -  Human Immunodeficiency Virus (HIV) positive

          -  Known history of active tuberculosis not adequately treated

          -  Prior use within 2 years preceding randomization or concomitant use of cladribine and
             mitoxantrone

          -  Prior use within 6 months preceding randomization or concomitant use of natalizumab,
             or any other immunosuppressive agents such as azathioprine, cyclophosphamide,
             cyclosporine, methotrexate, mycophenolate, or fingolimod

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840049</name>
      <address>
        <city>Cullman</city>
        <state>Alabama</state>
        <zip>35058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840005</name>
      <address>
        <city>Cordova</city>
        <state>Alaska</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840003</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840011</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840036</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840012</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840013</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840055</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840021</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840004</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609-4052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840047</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840034</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840037</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840033</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840041</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840028</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840016</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840031</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840030</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840009</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840023</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840015</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840027</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840006</name>
      <address>
        <city>Bismark</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840007</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840046</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840017</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43699</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840043</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840002</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840040</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840020</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840032</name>
      <address>
        <city>Vienna</city>
        <state>Virginia</state>
        <zip>22182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 032002</name>
      <address>
        <city>Argentina</city>
        <zip>1426</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 032003</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 032004</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036008</name>
      <address>
        <city>Bedford Park</city>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036005</name>
      <address>
        <city>Chatswood</city>
        <zip>2067</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036001</name>
      <address>
        <city>Heidelberg West</city>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036004</name>
      <address>
        <city>Kogarah</city>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036010</name>
      <address>
        <city>New Lambton</city>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 040001</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 040004</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056005</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056004</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056003</name>
      <address>
        <city>Hasselt</city>
        <zip>B-3590</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056006</name>
      <address>
        <city>La Louvière</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056002</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056001</name>
      <address>
        <city>Sijsele-Damme</city>
        <zip>8340</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056007</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076009</name>
      <address>
        <city>Joinville</city>
        <zip>89202-165</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076012</name>
      <address>
        <city>Passo Fundo</city>
        <zip>99010-180</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076003</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076007</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04024-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076013</name>
      <address>
        <city>Sao Paulo</city>
        <zip>08270-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124005</name>
      <address>
        <city>Calgary</city>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124004</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124003</name>
      <address>
        <city>Gatineau</city>
        <zip>J9J 0A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124006</name>
      <address>
        <city>Kingston</city>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124007</name>
      <address>
        <city>Montreal</city>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124008</name>
      <address>
        <city>Ottawa</city>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124002</name>
      <address>
        <city>Regina</city>
        <zip>S4T 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124001</name>
      <address>
        <city>Sherbrooke</city>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124009</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 152003</name>
      <address>
        <city>Santiago</city>
        <zip>7500710</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 152004</name>
      <address>
        <city>Santiago</city>
        <zip>838-0456</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 152005</name>
      <address>
        <city>Viña Del Mar</city>
        <zip>2570017</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170001</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170005</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170007</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170009</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 208002</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 233002</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 233001</name>
      <address>
        <city>Tartu</city>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 246003</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 246006</name>
      <address>
        <city>Hyvinkää</city>
        <zip>05800</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 246004</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 246002</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 246001</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250003</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250010</name>
      <address>
        <city>Clermont Ferrand Cedex 1</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250002</name>
      <address>
        <city>Lyon Cedex 03</city>
        <zip>69394</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250004</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250001</name>
      <address>
        <city>Nancy Cedex</city>
        <zip>54036</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250006</name>
      <address>
        <city>Nantes Cedex 01</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276009</name>
      <address>
        <city>Bad Mergentheim</city>
        <zip>97980</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276020</name>
      <address>
        <city>Bamberg</city>
        <zip>96047</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276003</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276015</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276016</name>
      <address>
        <city>Berlin</city>
        <zip>10713</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276021</name>
      <address>
        <city>Berlin</city>
        <zip>12099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276012</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276005</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276032</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40211</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276018</name>
      <address>
        <city>Erbach</city>
        <zip>64711</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276004</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276028</name>
      <address>
        <city>Freiburg</city>
        <zip>79098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276006</name>
      <address>
        <city>Gießen</city>
        <zip>35385</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276010</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276022</name>
      <address>
        <city>Hennigsdorf</city>
        <zip>16761</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276024</name>
      <address>
        <city>Kassel</city>
        <zip>34121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276001</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276013</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276023</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276002</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276031</name>
      <address>
        <city>Rostock</city>
        <zip>18055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276008</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276026</name>
      <address>
        <city>Wuppertal</city>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300002</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300001</name>
      <address>
        <city>Athens</city>
        <zip>11535</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300003</name>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300006</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 348002</name>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 348006</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 348010</name>
      <address>
        <city>Budapest</city>
        <zip>1204</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 348009</name>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 348003</name>
      <address>
        <city>Esztergom</city>
        <zip>2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 348001</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 348005</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 348007</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380009</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380002</name>
      <address>
        <city>Cefalù</city>
        <zip>90015</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380003</name>
      <address>
        <city>Fidenza</city>
        <zip>43036</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380004</name>
      <address>
        <city>Gallarate</city>
        <zip>21013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380012</name>
      <address>
        <city>Montichiari</city>
        <zip>25012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380010</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380011</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380006</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380005</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380008</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380014</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410002</name>
      <address>
        <city>Goyang-Si</city>
        <zip>410-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410004</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410001</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 440002</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 440004</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT-92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 440003</name>
      <address>
        <city>Siauliai</city>
        <zip>LT-76231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528001</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528005</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528002</name>
      <address>
        <city>Sittard-Geleen</city>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528006</name>
      <address>
        <city>Venray</city>
        <zip>5801 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 578002</name>
      <address>
        <city>Tønsberg</city>
        <zip>3116</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 620001</name>
      <address>
        <city>Amadora</city>
        <zip>2720-276</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 620002</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 620004</name>
      <address>
        <city>Coimbra</city>
        <zip>3041-801</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 620003</name>
      <address>
        <city>Setubal</city>
        <zip>2910-446</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643012</name>
      <address>
        <city>Kaluga</city>
        <zip>248007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643007</name>
      <address>
        <city>Kazan</city>
        <zip>420021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643001</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643013</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643006</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643004</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643015</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643010</name>
      <address>
        <city>Rostov-On-Don</city>
        <zip>344015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643009</name>
      <address>
        <city>Rostov-On-Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643016</name>
      <address>
        <city>Samara</city>
        <zip>443095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643005</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643011</name>
      <address>
        <city>St-Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643018</name>
      <address>
        <city>St-Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643003</name>
      <address>
        <city>St-Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643017</name>
      <address>
        <city>St-Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643002</name>
      <address>
        <city>St-Petersburg</city>
        <zip>197376</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643014</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 703002</name>
      <address>
        <city>Martin</city>
        <zip>03659</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 703001</name>
      <address>
        <city>Trnava</city>
        <zip>91775</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724001</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724002</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724009</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724003</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724004</name>
      <address>
        <city>Madrid</city>
        <zip>28005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724005</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724007</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724008</name>
      <address>
        <city>Sevilla</city>
        <zip>41008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 752004</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 752003</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 752001</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 788002</name>
      <address>
        <city>Manouba</city>
        <zip>2010</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 788005</name>
      <address>
        <city>Monastir</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 788004</name>
      <address>
        <city>Sfax</city>
        <zip>3029</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 788006</name>
      <address>
        <city>Tunis</city>
        <zip>1008</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826008</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826005</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826006</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826003</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826004</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826001</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Tunisia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2010</study_first_submitted>
  <study_first_submitted_qc>December 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2010</study_first_posted>
  <results_first_submitted>April 23, 2014</results_first_submitted>
  <results_first_submitted_qc>April 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 22, 2014</results_first_posted>
  <last_update_submitted>May 30, 2014</last_update_submitted>
  <last_update_submitted_qc>May 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment initiated in January 2011, was discontinued in December 2012 following the decision of the Sponsor to discontinue the study, the common treatment end date was defined as February 28th, 2013 (treatment duration between 24 and 108 weeks).
A total of 846 participants were screened at 185 sites in 28 countries.</recruitment_details>
      <pre_assignment_details>Randomization was stratified by investigational site and Interferon-beta (IFN-beta) dose level (high/low). Assignment to groups was done centrally using an Interactive Voice Response System (IVRS) in a 1:1:1 ratio after confirmation of selection criteria. A total of 534 participants were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo + IFN-beta</title>
          <description>Placebo (for teriflunomide) once daily concomitantly with IFN-beta.</description>
        </group>
        <group group_id="P2">
          <title>Teriflunomide 7 mg + IFN-beta</title>
          <description>Teriflunomide 7 mg once daily concomitantly with IFN-beta.</description>
        </group>
        <group group_id="P3">
          <title>Teriflunomide 14 mg + IFN-beta</title>
          <description>Teriflunomide 14 mg once daily concomitantly with IFN-beta.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="177">Randomized.</participants>
                <participants group_id="P2" count="178">Randomized.</participants>
                <participants group_id="P3" count="179">Randomized.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="178"/>
                <participants group_id="P3" count="179">One participant received teriflunomide 7 mg.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="177"/>
                <participants group_id="P2" count="178"/>
                <participants group_id="P3" count="179"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor Compliance to Protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Early Termination of Study</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="149"/>
                <participants group_id="P3" count="146"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not Treated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Than Above</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized population: all randomized participants according to the treatment group to which they were assigned.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo + IFN-beta</title>
          <description>Placebo (for teriflunomide) once daily concomitantly with IFN-beta.</description>
        </group>
        <group group_id="B2">
          <title>Teriflunomide 7 mg + IFN-beta</title>
          <description>Teriflunomide 7 mg once daily concomitantly with IFN-beta.</description>
        </group>
        <group group_id="B3">
          <title>Teriflunomide 14 mg + IFN-beta</title>
          <description>Teriflunomide 14 mg once daily concomitantly with IFN-beta.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="177"/>
            <count group_id="B2" value="178"/>
            <count group_id="B3" value="179"/>
            <count group_id="B4" value="534"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.3" spread="8.9"/>
                    <measurement group_id="B2" value="38.7" spread="9.5"/>
                    <measurement group_id="B3" value="37.7" spread="9.2"/>
                    <measurement group_id="B4" value="38.2" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="114"/>
                    <measurement group_id="B4" value="352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Due to the small sample size in some countries, the countries were pooled as follows:
America: Argentina, Brazil, Canada, Chile, Columbia, The United States
Western Europe: Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Portugal, Spain, Sweden, The United Kingdom
Eastern Europe = Estonia, Greece, Hungary, Lithuania, Russian Federation, Slovakia
Asia, Africa and Australia = Australia, Republic of Korea, Tunisia</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Western Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eastern Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asia, Africa and Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time Since First Diagnosis of Multiple Sclerosis (MS)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.0" spread="5.6"/>
                    <measurement group_id="B2" value="6.6" spread="5.6"/>
                    <measurement group_id="B3" value="6.8" spread="5.9"/>
                    <measurement group_id="B4" value="6.8" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of MS Relapses</title>
          <description>The information was not available for one participant in the &quot;Teriflunomide 14 mg + IFN-beta&quot; group.</description>
          <units>MS relapses</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Within the past year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B2" value="1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="B3" value="1" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B4" value="1" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within the past 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="B2" value="2" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="B3" value="2" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="B4" value="2" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time Since Most Recent MS Relapse Onset</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.0" spread="8.29" lower_limit="1.0" upper_limit="75.0"/>
                    <measurement group_id="B2" value="5.0" spread="4.83" lower_limit="1.0" upper_limit="36.0"/>
                    <measurement group_id="B3" value="4.0" spread="15.36" lower_limit="1.0" upper_limit="174.0"/>
                    <measurement group_id="B4" value="5.0" spread="10.47" lower_limit="1.0" upper_limit="174.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MS Subtype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Relapsing Remitting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="173"/>
                    <measurement group_id="B3" value="175"/>
                    <measurement group_id="B4" value="522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondary Progressive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Relapsing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Expanded Disability Status Scale (EDSS) Score</title>
          <description>EDSS is an ordinal scale in half-point increments that qualifies disability in participants with MS. It consists of 8 ordinal rating scales assessing seven functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation. EDSS total score ranges from 0 (normal neurological examination) to 10 (death due to MS).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.67" spread="1.25"/>
                    <measurement group_id="B2" value="2.63" spread="1.37"/>
                    <measurement group_id="B3" value="2.64" spread="1.18"/>
                    <measurement group_id="B4" value="2.65" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dose Level of Interferon-beta (IFN-beta) Based on IVRS</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>High dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Annualized Relapse Rate (ARR) (Poisson Regression Estimates)</title>
        <description>ARR is the total number of confirmed relapses that occurred during the treatment period divided by the total number of patient-years treated. Each episode of relapse (appearance, or worsening of a clinical symptom that was stable for at least 30 days, that persisted for a minimum of 24 hours in the absence of fever) was to be confirmed by an increase in Expanded Disability Status Scale (EDSS) score or Functional System scores. To account for the different treatment durations among participants, a Poisson regression model with robust error variance was used (total number of confirmed relapses as response variable; log-transformed treatment duration as &quot;offset&quot; variable; treatment group, region of enrollment and IFN-beta dose stratum, and number of relapses in the year prior to randomization as covariates).</description>
        <time_frame>Up to a maximum of 108 weeks depending on time of enrollment</time_frame>
        <population>Intent-to-treat (ITT) population: all randomized and treated participants. Participants were considered in the treatment group to which they were randomized regardless of the drug they actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + IFN-beta</title>
            <description>Placebo (for teriflunomide) once daily concomitantly with IFN-beta.</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg + IFN-beta</title>
            <description>Teriflunomide 7 mg once daily concomitantly with IFN-beta.</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg + IFN-beta</title>
            <description>Teriflunomide 14 mg once daily concomitantly with IFN-beta.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Relapse Rate (ARR) (Poisson Regression Estimates)</title>
          <description>ARR is the total number of confirmed relapses that occurred during the treatment period divided by the total number of patient-years treated. Each episode of relapse (appearance, or worsening of a clinical symptom that was stable for at least 30 days, that persisted for a minimum of 24 hours in the absence of fever) was to be confirmed by an increase in Expanded Disability Status Scale (EDSS) score or Functional System scores. To account for the different treatment durations among participants, a Poisson regression model with robust error variance was used (total number of confirmed relapses as response variable; log-transformed treatment duration as &quot;offset&quot; variable; treatment group, region of enrollment and IFN-beta dose stratum, and number of relapses in the year prior to randomization as covariates).</description>
          <population>Intent-to-treat (ITT) population: all randomized and treated participants. Participants were considered in the treatment group to which they were randomized regardless of the drug they actually received.</population>
          <units>relapses per patient-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.298" lower_limit="0.206" upper_limit="0.432"/>
                    <measurement group_id="O2" value="0.242" lower_limit="0.152" upper_limit="0.386"/>
                    <measurement group_id="O3" value="0.238" lower_limit="0.162" upper_limit="0.351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brain Magnetic Resonance Imaging (MRI) Assessment: Number of Gadolinium Enhancing (Gd-enhancing) T1-lesions Per Scan (Poisson Regression Estimates)</title>
        <description>Number of Gd-enhancing T1-lesions per scan is the total number of Gd-enhancing T1-lesions that occurred during the treatment period divided by the total number of scans performed during the treatment period. To account for the different number of scans among participants, a Poisson regression model with robust error variance was used (total number of Gd-enhancing T1-lesions as response variable; log-transformed number of scans as offset variable; treatment group, region of enrollment, IFN-beta dose stratum and baseline number of Gd-enhancing T1-lesions as covariates).</description>
        <time_frame>Up to a maximum of 108 weeks depending on time of enrollment</time_frame>
        <population>ITT population as previously defined but including only participants who had post-baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + IFN-beta</title>
            <description>Placebo (for teriflunomide) once daily concomitantly with IFN-beta.</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg + IFN-beta</title>
            <description>Teriflunomide 7 mg once daily concomitantly with IFN-beta.</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg + IFN-beta</title>
            <description>Teriflunomide 14 mg once daily concomitantly with IFN-beta.</description>
          </group>
        </group_list>
        <measure>
          <title>Brain Magnetic Resonance Imaging (MRI) Assessment: Number of Gadolinium Enhancing (Gd-enhancing) T1-lesions Per Scan (Poisson Regression Estimates)</title>
          <description>Number of Gd-enhancing T1-lesions per scan is the total number of Gd-enhancing T1-lesions that occurred during the treatment period divided by the total number of scans performed during the treatment period. To account for the different number of scans among participants, a Poisson regression model with robust error variance was used (total number of Gd-enhancing T1-lesions as response variable; log-transformed number of scans as offset variable; treatment group, region of enrollment, IFN-beta dose stratum and baseline number of Gd-enhancing T1-lesions as covariates).</description>
          <population>ITT population as previously defined but including only participants who had post-baseline data.</population>
          <units>lesions per scan</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.542" lower_limit="0.344" upper_limit="0.855"/>
                    <measurement group_id="O2" value="0.257" lower_limit="0.127" upper_limit="0.523"/>
                    <measurement group_id="O3" value="0.158" lower_limit="0.070" upper_limit="0.360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to 12-Week Sustained Disability Progression</title>
        <description>The 12-week sustained disability progression was defined as an increase from baseline of at least 1-point in EDSS score (at least 0.5-point for participants with baseline EDSS score &gt;5.5) that persisted for at least 12 weeks. Probability of disability progression was to be estimated using Kaplan-Meier method.</description>
        <time_frame>Up to a maximum of 108 weeks depending on time of enrollment</time_frame>
        <population>Data for this outcome was not analyzed because of insufficient data after early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + IFN-beta</title>
            <description>Placebo (for teriflunomide) once daily concomitantly with IFN-beta.</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg + IFN-beta</title>
            <description>Teriflunomide 7 mg once daily concomitantly with IFN-beta.</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg + IFN-beta</title>
            <description>Teriflunomide 14 mg once daily concomitantly with IFN-beta.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to 12-Week Sustained Disability Progression</title>
          <description>The 12-week sustained disability progression was defined as an increase from baseline of at least 1-point in EDSS score (at least 0.5-point for participants with baseline EDSS score &gt;5.5) that persisted for at least 12 weeks. Probability of disability progression was to be estimated using Kaplan-Meier method.</description>
          <population>Data for this outcome was not analyzed because of insufficient data after early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brain MRI Assessment: Volume of Gd-enhancing T1-lesions Per MRI Scan</title>
        <description>Total volume of Gd-enhancing T1-lesions per scan is the sum of the volumes of Gd-enhancing T1-lesions observed during the treatment period divided by the total number of scans performed during the treatment period.</description>
        <time_frame>Up to a maximum of 108 weeks depending on time of enrollment</time_frame>
        <population>ITT population as previously defined but including only participants who had post-baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + IFN-beta</title>
            <description>Placebo (for teriflunomide) once daily concomitantly with IFN-beta.</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg + IFN-beta</title>
            <description>Teriflunomide 7 mg once daily concomitantly with IFN-beta.</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg + IFN-beta</title>
            <description>Teriflunomide 14 mg once daily concomitantly with IFN-beta.</description>
          </group>
        </group_list>
        <measure>
          <title>Brain MRI Assessment: Volume of Gd-enhancing T1-lesions Per MRI Scan</title>
          <description>Total volume of Gd-enhancing T1-lesions per scan is the sum of the volumes of Gd-enhancing T1-lesions observed during the treatment period divided by the total number of scans performed during the treatment period.</description>
          <population>ITT population as previously defined but including only participants who had post-baseline data.</population>
          <units>milliliters per scan</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.045"/>
                    <measurement group_id="O2" value="0.009"/>
                    <measurement group_id="O3" value="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brain MRI Assessment: Change From Baseline in Total Lesion Volume (Burden of Disease) at Week 24</title>
        <description>The total lesion volume (burden of disease) is the total volumes of hyperintense on T2 plus hypointense on T1 as measured by MRI scan. Least-square means were estimated using a Mixed-effect model with repeated measures (MMRM) on cubic root transformed volume data with factors for treatment, region, IFN-beta dose stratum, visit, treatment-by-visit interaction, cubic root transformed baseline burden of disease, and baseline-by-visit interaction.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>ITT population as previously defined but including only participants who had post-baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + IFN-beta</title>
            <description>Placebo (for teriflunomide) once daily concomitantly with IFN-beta.</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg + IFN-beta</title>
            <description>Teriflunomide 7 mg once daily concomitantly with IFN-beta.</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg + IFN-beta</title>
            <description>Teriflunomide 14 mg once daily concomitantly with IFN-beta.</description>
          </group>
        </group_list>
        <measure>
          <title>Brain MRI Assessment: Change From Baseline in Total Lesion Volume (Burden of Disease) at Week 24</title>
          <description>The total lesion volume (burden of disease) is the total volumes of hyperintense on T2 plus hypointense on T1 as measured by MRI scan. Least-square means were estimated using a Mixed-effect model with repeated measures (MMRM) on cubic root transformed volume data with factors for treatment, region, IFN-beta dose stratum, visit, treatment-by-visit interaction, cubic root transformed baseline burden of disease, and baseline-by-visit interaction.</description>
          <population>ITT population as previously defined but including only participants who had post-baseline data.</population>
          <units>milliliter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.008" spread="0.021"/>
                    <measurement group_id="O2" value="-0.011" spread="0.021"/>
                    <measurement group_id="O3" value="-0.044" spread="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Relapse: Kaplan-Meier Estimates of the Probability of no Relapse at Week 24, 48, and 72</title>
        <description>Probability of no relapse at 24, 48 and 72 weeks was estimated using Kaplan-Meier method on the time to relapse defined as the time from randomization to first EDSS confirmed relapse. Participants free of confirmed relapse (no EDSS confirmed relapse observed on treatment) were censored at the date of the last study drug intake. Kaplan-Meier method consists in computing probabilities of non-occurrence of event at any observed time of event and multiplying successive probabilities for time &lt;=t by any earlier computed probabilities to estimate the probability of being event-free for the amount of time t.</description>
        <time_frame>Up to a maximum of 108 weeks depending on time of enrollment</time_frame>
        <population>ITT population as previously defined.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + IFN-beta</title>
            <description>Placebo (for teriflunomide) once daily concomitantly with IFN-beta.</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg + IFN-beta</title>
            <description>Teriflunomide 7 mg once daily concomitantly with IFN-beta.</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg + IFN-beta</title>
            <description>Teriflunomide 14 mg once daily concomitantly with IFN-beta.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Relapse: Kaplan-Meier Estimates of the Probability of no Relapse at Week 24, 48, and 72</title>
          <description>Probability of no relapse at 24, 48 and 72 weeks was estimated using Kaplan-Meier method on the time to relapse defined as the time from randomization to first EDSS confirmed relapse. Participants free of confirmed relapse (no EDSS confirmed relapse observed on treatment) were censored at the date of the last study drug intake. Kaplan-Meier method consists in computing probabilities of non-occurrence of event at any observed time of event and multiplying successive probabilities for time &lt;=t by any earlier computed probabilities to estimate the probability of being event-free for the amount of time t.</description>
          <population>ITT population as previously defined.</population>
          <units>percent probability of no relapse</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent probability of no relapse at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.9" lower_limit="75.8" upper_limit="88.0"/>
                    <measurement group_id="O2" value="86.8" lower_limit="81.4" upper_limit="92.1"/>
                    <measurement group_id="O3" value="87.1" lower_limit="81.8" upper_limit="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent probability of no relapse at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3" lower_limit="58.8" upper_limit="75.8"/>
                    <measurement group_id="O2" value="80.6" lower_limit="73.3" upper_limit="87.8"/>
                    <measurement group_id="O3" value="80.8" lower_limit="73.9" upper_limit="87.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent probability of no relapse at Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.3" lower_limit="45.4" upper_limit="71.2"/>
                    <measurement group_id="O2" value="78.2" lower_limit="69.8" upper_limit="86.6"/>
                    <measurement group_id="O3" value="73.1" lower_limit="62.2" upper_limit="83.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fatigue Impact Scale (FIS) Total Score at Week 24</title>
        <description>FIS is a participant-reported scale that qualifies the impact of fatigue on daily life in participants with MS.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Data for this outcome was not analyzed because of insufficient data after early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + IFN-beta</title>
            <description>Placebo (for teriflunomide) once daily concomitantly with IFN-beta.</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg + IFN-beta</title>
            <description>Teriflunomide 7 mg once daily concomitantly with IFN-beta.</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg + IFN-beta</title>
            <description>Teriflunomide 14 mg once daily concomitantly with IFN-beta.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fatigue Impact Scale (FIS) Total Score at Week 24</title>
          <description>FIS is a participant-reported scale that qualifies the impact of fatigue on daily life in participants with MS.</description>
          <population>Data for this outcome was not analyzed because of insufficient data after early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short Form Generic Health Survey - 36 Items, Version 2 (SF-36v2) Summary Scores at Week 24</title>
        <description>SF-36 scale is a generic, self-administered, health-related quality-of-life (QOL) instrument.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Data for this outcome was not analyzed because of insufficient data after early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + IFN-beta</title>
            <description>Placebo (for teriflunomide) once daily concomitantly with IFN-beta.</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg + IFN-beta</title>
            <description>Teriflunomide 7 mg once daily concomitantly with IFN-beta.</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg + IFN-beta</title>
            <description>Teriflunomide 14 mg once daily concomitantly with IFN-beta.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short Form Generic Health Survey - 36 Items, Version 2 (SF-36v2) Summary Scores at Week 24</title>
          <description>SF-36 scale is a generic, self-administered, health-related quality-of-life (QOL) instrument.</description>
          <population>Data for this outcome was not analyzed because of insufficient data after early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resource Utilization When Relapse</title>
        <description>Resource utilization each time a participant experiences an MS relapse, specifically the number of hospitalizations, the number of over night spent in the hospital and number of intensive care admissions if hospitalized were to be reported.</description>
        <time_frame>Up to a maximum of 108 weeks depending on time of enrollment</time_frame>
        <population>Data for this outcome was not analyzed because of insufficient data after early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + IFN-beta</title>
            <description>Placebo (for teriflunomide) once daily concomitantly with IFN-beta.</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg + IFN-beta</title>
            <description>Teriflunomide 7 mg once daily concomitantly with IFN-beta.</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg + IFN-beta</title>
            <description>Teriflunomide 14 mg once daily concomitantly with IFN-beta.</description>
          </group>
        </group_list>
        <measure>
          <title>Resource Utilization When Relapse</title>
          <description>Resource utilization each time a participant experiences an MS relapse, specifically the number of hospitalizations, the number of over night spent in the hospital and number of intensive care admissions if hospitalized were to be reported.</description>
          <population>Data for this outcome was not analyzed because of insufficient data after early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overview of Adverse Events (AEs)</title>
        <description>AEs are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.</description>
        <time_frame>First study drug intake up to 28 days after last study drug intake, for up to 112 weeks</time_frame>
        <population>Safety population: all randomized and treated participants. Participants were included in the treatment group according to the drug actually received.The participant randomized to Teriflunomide 14 mg group who received Teriflunomide 7 mg was analyzed in the Teriflunomide 7 mg group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + IFN-beta</title>
            <description>Placebo (for teriflunomide) once daily concomitantly with IFN-beta.</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg + IFN-beta</title>
            <description>Teriflunomide 7 mg once daily concomitantly with IFN-beta.</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg + IFN-beta</title>
            <description>Teriflunomide 14 mg once daily concomitantly with IFN-beta.</description>
          </group>
        </group_list>
        <measure>
          <title>Overview of Adverse Events (AEs)</title>
          <description>AEs are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.</description>
          <population>Safety population: all randomized and treated participants. Participants were included in the treatment group according to the drug actually received.The participant randomized to Teriflunomide 14 mg group who received Teriflunomide 7 mg was analyzed in the Teriflunomide 7 mg group.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="179"/>
                <count group_id="O3" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="140"/>
                    <measurement group_id="O3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE Leading to Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE Leading to Study Drug Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Liver Function: Number of Participants With Potentially Clinically Significant Abnormalities (PCSA)</title>
        <description>PCSA values are abnormal values considered medically important by the Sponsor according to predefined criteria based on literature review. Hepatic parameters thresholds were defined as follows: Alanine Aminotransferase (ALT) &gt;3, 5 or 10 Upper Limit of Normal (ULN); Aspartate Aminotransferase (AST) &gt;3, 5 or 10 ULN; Alkaline Phosphatase &gt;1.5 ULN; Total Bilirubin (TB) &gt;1.5 ULN; and ALT &gt;3 ULN and TB &gt;2 ULN.</description>
        <time_frame>First study drug intake up to 28 days after last study drug intake, for up to 112 weeks</time_frame>
        <population>Safety population as previously defined but including only participants who had post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + IFN-beta</title>
            <description>Placebo (for teriflunomide) once daily concomitantly with IFN-beta.</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg + IFN-beta</title>
            <description>Teriflunomide 7 mg once daily concomitantly with IFN-beta.</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg + IFN-beta</title>
            <description>Teriflunomide 14 mg once daily concomitantly with IFN-beta.</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Function: Number of Participants With Potentially Clinically Significant Abnormalities (PCSA)</title>
          <description>PCSA values are abnormal values considered medically important by the Sponsor according to predefined criteria based on literature review. Hepatic parameters thresholds were defined as follows: Alanine Aminotransferase (ALT) &gt;3, 5 or 10 Upper Limit of Normal (ULN); Aspartate Aminotransferase (AST) &gt;3, 5 or 10 ULN; Alkaline Phosphatase &gt;1.5 ULN; Total Bilirubin (TB) &gt;1.5 ULN; and ALT &gt;3 ULN and TB &gt;2 ULN.</description>
          <population>Safety population as previously defined but including only participants who had post-baseline values.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="179"/>
                <count group_id="O3" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT &gt;3 ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT &gt;5 ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT &gt;10 ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST &gt;3 ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST &gt;5 ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST &gt;10 ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase &gt;1.5 ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TB &gt;1.5 ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT &gt;3 ULN and TB &gt;2 ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All AEs were collected regardless of seriousness or relationship to the drug, spanning from signature of the Informed Consent up to the last visit.</time_frame>
      <desc>The analysis was performed on the safety population and included all AEs that developed or worsened from first study drug intake up to 28 days after last study drug intake, for up to 112 weeks. Participants were included in the treatment group according to the drug actually received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo + IFN-beta</title>
          <description>Placebo (for teriflunomide) once daily concomitantly with IFN-beta.</description>
        </group>
        <group group_id="E2">
          <title>Teriflunomide 7 mg + IFN-beta</title>
          <description>Teriflunomide 7 mg once daily concomitantly with IFN-beta.</description>
        </group>
        <group group_id="E3">
          <title>Teriflunomide 14 mg + IFN-beta</title>
          <description>Teriflunomide 14 mg once daily concomitantly with IFN-beta.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Testicular seminoma (pure)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="104" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The early termination of study with reduced sample size and participant follow-up impacts the power and interpretability, and limits the ability to assess the overall benefit/risk of adjunctive therapy. Termination was not due to any safety concerns.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>Sanofi</organization>
      <email>Contact-us@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

